With the rapid development of large-scale genome-sequencing technologies, numerous studies have investigated large numbers of molecular biomarkers for GBM, including 1p/19q codeletion, telomerase reverse transcriptase (TERT) promoter mutations, tumor protein 53 (TP53) mutations, X-linked helicase II (ATRX) mutations, and isocitrate dehydrogenase (IDH) mutation [14–16]. This evidence concerns the gene TERT and glioblastoma.